Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment
Objective: to comparatively assess the weighted average costs associated with the use of alogliptin-pioglitazone combination versus glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Material and methods. A retrospective study involved pharmacoeconomic analysis, including cost-minimization analys...
Saved in:
| Main Authors: | S. К. Zyryanov, I. N. Dyakov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2025-02-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/1136 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
by: M. V. Shestakova, et al.
Published: (2021-07-01) -
Assessment of the effectiveness and safety of fixed-dose combination of alogliptin and pioglitazone in real clinical practice: results of the PROsperity study
by: M. V. Shestakova, et al.
Published: (2025-05-01) -
Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes
by: V. V. Salukhov, et al.
Published: (2024-03-01) -
SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)